Stopping CDK4/6 inhibitors in advanced breast cancer
Part of Cancer, Skin clinical trials.
This trial looks at what happens when women with advanced hormone-positive, HER2-negative breast cancer stop taking a CDK4/6 inhibitor after at least a year of successful treatment. The goal is to see if it's safe to take a break from the CDK4/6 inhibitor while continuing hormone therapy alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are female and at least 18 years old.
- Your breast cancer has spread to other parts of the body, is hormone receptor positive (ER+) and HER2 negative.
- You have been taking a CDK4/6 inhibitor (like palbociclib, ribociclib, or abemaciclib) plus hormone therapy for at least 12 months and your cancer has not progressed.
- You are postmenopausal.
- You do not have active brain metastases.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is for people with a common type of breast cancer that is hormone-receptor-positive and HER2-negative, and has a high risk of coming back. It looks at how well patients take a type of targeted therapy (CDK4/6 inhibitors) combined with hormone therapy after surgery, to help prevent recurrence.
This study looks at how well a type of targeted therapy (called CDK4/6 inhibitors) combined with hormone therapy works as the first treatment for advanced breast cancer that is hormone receptor-positive and HER2-negative. Researchers want to find patterns that could help predict which patients benefit most.
This study looks at how well CDK4/6 inhibitors (a type of targeted therapy) work in real-world patients with HR+/HER2- advanced breast cancer. By collecting medical data from people treated at this hospital, doctors hope to learn more about the effectiveness and safety of these drugs in everyday practice.
This trial tests whether it is safe to skip chemotherapy after surgery for certain patients with early-stage, hormone-receptor positive, HER2-negative breast cancer that has not spread to lymph nodes. Instead, they would receive hormone therapy plus a targeted CDK4/6 inhibitor (a pill that blocks cancer cell growth).
This trial tests whether an artificial intelligence (AI) tool can help doctors decide if it is safe and effective to give you a second course of a CDK4/6 inhibitor drug (like palbociclib, ribociclib, or abemaciclib) plus hormone therapy for advanced (unresectable or metastatic) HR+/HER2- breast cancer. The goal is to only treat people whose cancer is likely to respond based on a special AI analysis of their tumor tissue.
This phase 2 trial compares ribociclib, palbociclib, and abemaciclib to see how each one affects your body’s immune response in estrogen- and/or progesterone-receptor–positive, HER2-negative early breast cancer. If you fit the stage and health requirements, joining could help doctors learn which treatment best “modulates” the immune system.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.